Pacritinib (NCT07226713)

Name: Pacritinib trial for Prostate Cancer (NCT07226713)
Uploaded: 2026-10-31T17:28:15.896Z
Duration: 1 min 20 s
Description: Pacritinib trial for Prostate Cancer (NCT07226713). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07226713.

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors: a one-minute explainerNCT072267131 min

Pacritinib trial for Prostate Cancer (NCT07226713). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with metastatic castration-resistant prostate cancer that progressed during or after an androgen-receptor signaling inhibitor. A fresh biopsy within 30 days must show activated STAT5 in more than five percent of cancer cells.

The idea: pacritinib blocks JAK2, disrupting the JAK-STAT signaling pathway. Participants take 200 milligrams orally twice daily. Researchers assess cancer control on scans at six months. Prior JAK2 inhibitors are excluded; chemotherapy has restrictions.

This phase 2 study plans 32 patients. The Medical College of Wisconsin leads it in Milwaukee, the only recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.